Drug Trial Radar · NCT06146088
Lot-to-lot Consistency Study of Three Commercial Batches of Enterovirus 71 Vaccine
Last checked: Nov 20, 2026Latest source record: Jan 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,500
Planned (sponsor's estimate)
Start
Nov 25, 2023
Primary completion
Mar 31, 2024
Study completion Jul 15, 2026
Sponsor
- Lead sponsor
- Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centers for Disease Control and Prevention, China
- First posted
- Nov 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 35 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, blinded study to evaluate the lot-to-lot consistency of immunogenicity, safety, and immune persistence of three consecutive manufacturing lots of EV71 vaccine, in 1500 children aged 6-35 months. The primary immunogenicity endpoint is the anti-EV71 neutralizing antibody geometric mean titer (GMT) 30 days after the final dose. The secondary immunogenicity endpoints are the geometric mean fold increases and seroconversion rates of anti-EV71 neutralizing antibodies 30 days after the final dose. The immune persistence endpoints are the seropositive rates as well as GMT of anti-EV71 neutralizing antibodies 12 and 24 months after the final dose. The safety endpoints are the number of adverse events/reactions within 30 minutes after each dose, the number of solicited adverse events/reactions within 7 days after each dose, the number of unsolicited adverse events/reactions within 30 days after each dose, and the number of serious adverse events (SAE) from the first dose to 6 months post the final dose.
Conditions
- Hand, Foot and Mouth Disease
Interventions
EV71 VaccineBiological
Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
Primary outcomes
What the sponsor says the trial is designed to measure.
- Immunogenicity index-geometric mean titer (GMT) of neutralizing antibodyTime frame: Day 30 after the second vaccination
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Chencang Center for Disease Prevention and Control
Baoji, Shaan XI, China · Not yet recruiting
Ningqiang Center for Disease Prevention and Control
Hanzhong, Shaan XI, China · Recruiting
Fuping Center for Disease Prevention and Control
Weinan, Shaan XI, China · Not yet recruiting
Jingyang Center for Disease Prevention and Control
Xianyang, Shaan XI, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.